Novogenia AG, an international healthcare company specializing in human genetics and personalized products, announced the U.S. market launch of its new MGT Plus methylation test. The launch, in collaboration with U.S. partner 10X Health, marks an expansion of their joint product pipeline and strengthens their international collaboration in genetic analysis and longevity.
Methylation is a fundamental biochemical process involved in numerous metabolic and regulatory functions in the human body. It can significantly influence the function and processing of biological molecules, including vitamins and neurotransmitters. While commercially available tests typically analyze only a limited number of relevant genes, MGT Plus covers a total of 27 genes, providing a more comprehensive picture of methylation processes across six interconnected biological pathways: energy and nutrient metabolism, stress and neurotransmitter regulation, vascular health, immune health, and cellular health.
Dr. Daniel Wallerstorfer, CEO of Novogenia AG, emphasized the significance of the expanded test: “With MGT Plus, we are enabling a more comprehensive understanding of biochemical methylation processes. The significantly expanded scope of analysis provides deeper insights into genetic factors involved in methylation-related metabolic pathways in the body, creating new opportunities for more personalized prevention and health strategies. Our close collaboration with our U.S. partner 10X Health underscores our commitment to making scientific innovations accessible internationally and actively advancing personalized approaches to preventive health.”
The global direct-to-consumer testing market is experiencing strong growth. In 2025, the market size reached approximately $4.7 billion and is projected to grow to more than $16.0 billion by 2033. The genetic testing sector is a key driver, representing the largest segment with over 40% market share. North America leads this sector, accounting for around 50% of the global market volume in 2025. This growth is fueled by increasing consumer interest in personalized health information, prevention, and tailored health services.
The launch of MGT Plus could have significant implications for the healthcare industry. By offering a more comprehensive methylation analysis, Novogenia aims to provide deeper insights into genetic predispositions, enabling more personalized prevention and treatment strategies. This aligns with the broader trend toward precision medicine and could influence how healthcare providers approach patient care.
For consumers, the test may offer a clearer understanding of their genetic makeup related to metabolism, stress response, and immune function, potentially guiding lifestyle and dietary choices. For the industry, this launch underscores the competitive nature of the genetic testing market, where companies are striving to offer more comprehensive and actionable insights.
Novogenia's focus on international expansion, particularly in the North American market, reflects the strategic importance of this region in the global genetic testing landscape. The collaboration with 10X Health is expected to leverage both companies' strengths to bring innovative genetic analysis to a wider audience.
As the demand for personalized health solutions continues to rise, the introduction of MGT Plus represents a step forward in making advanced genetic testing more accessible and informative. The test's broader scope could set a new standard in methylation analysis, potentially influencing future product developments in the industry.
